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Summary The sensitivity of eight cell lines established from treated and untreated patients with small cell
carcinoma of the lung (SCCL) was tested in the clonogenic assay with 1 h and continuous exposure to
aclarubicin (ACLA), adriamycin (ADR), daunorubicin (DAU) and mitoxantrone (MITO). The sensitivity to
ADR, DAU and MITO covariated, and varied with a factor of five. The sensitivity to ACLA was independent
of the sensitivity to ADR and varied only within a factor of two. Only ACLA showed pronounced increased
potency with continuous incubation, and ACLA was the most potent drug in the three cell lines least sensitive
to ADR. Two resistant cell lines were selected by treating NCI-H69 in vitro with DAU. One cell line (9-fold
resistant to DAU) expressed large amounts of P-glycoprotein, the other cell line (4-fold resistant to DAU) had
barely detectable glycoprotein. Both lines acquired resistance to ADR, ACLA and MITO. The cross-resistance
to ACLA and MITO was only partial and ACLA was still the most potent drug on these lines. The sensitivity
to ACLA of the cell lines least sensitive to ADR suggest that ACLA partially circumvents mechanisms of
multidrug resistance. Together with the pronounced increase in potency with prolonged exposure, these results
suggest that ACLA has a mechanism of action different from the 'classical' anthracyclines. In this context
mitoxantrone is more similar to the classical anthracyclines although its structure is more dissimilar.
The anthracyclines are among the most potent drugs in the
treatment of a wide range of human neoplasms. Develop-
ment of resistance to the drugs is a major problem, and
much effort is devoted to the search of new anthracyclines
without cross-resistance to the parent drugs. The anthracyc-
line aclarubicin (ACLA) was isolated in 1975 by Oki et al.
(1975) and activitiy was found in acute myelogenic leukaemia
(AML) refractory to treatment with daunorubicin (DAU)
and cytarbine (Pedersen-Bjergaard et al., 1984; Warrel et al.,
1982). Recently, a phase III trial has found ACLA to be
superior to DAU in the treatment of de novo AML (Hansen
et al., 1988). In a previous study on the inter-experimental
variation in the clonogenic assay we observed that the sen-
sitivity pattern to ACLA in a panel of small cell lung cancer
(SCCL) cell lines was different from the sensitivity to
adriamycin (ADR), DAU and mitoxantrone (MITO) after
short time incubation (Jensen et al., 1989). The present inves-
tigations were initiated to further elucidate the differences
between ACLA and the other analogues. A murine tumour
has recently been described to be relatively more sensitive to
MITO than the tested human tumours (Hill et al., 1989). The
murine tumour cells P388 and Ehrlich were included in the
present study for comparision to the human cell lines and the
in vivo antitumour models. As the relationship between dura-
tion of drug exposure and cytotoxicity can give valuable
information on mechanisms of toxicity (Roed et al., 1986),
the patterns of sensitivity to ACLA, ADR, DAU and MITO
after short time exposure were compared with the cytotox-
icity and cross-resistance patterns after prolonged administra-
tion.
Two DAU resistant SCCL cell lines with pronounced
differences in expression of the multidrug resistant (MDR)
related P-glycoprotein were selected in vitro and compared to
the parental line.
Materials and methods
Drugs
ADR (Carlo Erba), DAU (Rhone Poulenc) and ACLA
(Lundbeck) were dissolved in sterile water just before use.
MITO (Lederle) was supplied in aqueous solution for
infusion. Drug solutions were made with tissue culture
medium.
Cell lines
The human SCCL cell lines used were NCI-H69, NCI-N592,
NCI-H249CL5, NCI-N417, OC-NYH (also designated GLC-
2), OC-TOL (GLC-3), GLC-16 and SCLC-86M1. Their
source, relation to therapy and growth behaviour in vitro are
described in Table I. The serially transplanted mouse
tumours Ehrlich ascites tumour and P388 leukaemia were
transferred to medium and established as in vitro cell lines
without changes in DNA content. After three passages in
vitro the cell lines were used in experiments. Resistance to
DAU was obtained by treating a total of approximately
5 x 10' NCI-H69 cells with 0.1 Lgml-' of DAU con-
tinuously. The surviving cells were pooled and passaged three
times in medium with 0.1 lg ml-' DAU. Cell line NCI-
H69 /DAU4 was maintained in drug-free medium for 4
weeks before testing. Cell line NCI-H69/DAU8 was main-
tained in drug-free medium for 8 weeks before testing.
All cell lines were maintained at 37°C in Roswell Park
Memorial Institute medium 1640 with 10% fetal calf serum
in a humidified atmosphere with 7.5% CO2. The cell lines
were free of mycoplasm contamination, and the genetic
stability of the cell lines was checked by flow cytometric
DNA-analysis.
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Clonogenic assay
Cell survival was assessed by colony formation in soft agar as
previously described (Roed et al., 1987). In experiments with
1 h drug exposure the growth conditions before sensitivity
testing were standardised, i.e. 5 x 105 cells were passed to
15 ml of medium and left untouched in flasks for 5 days
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Table I Source, relation to chemotherapy and growth behaviour in vitro ofthe cell lines
used
Established Growth
Cell line References from Prior therapy behaviour
NCI-H69 Carney et al. (1985) PIE CTX MTX CCNU* s
VCR ADR PRO
NCI-N592 Carney et al. (1985) BM MTX* s
NCI-N417 Carney et al. (1985) LT no s
NCI-H249CL5 Carney et al. (1985) BM MTX* s
OC-NYH de Leij et al. (1985) PIE no mon
OC-TOL de Leij et al. (1985) PIE no s
GLCI6 Berendsen et al. (1988) LT CTX VP-16 ADR s
SCLC-86MI Bepler et al. (1987) PIE no s
PIE, pleural effusion; BM, bone marrow; LT, lung tumour; CTX, cyclofosfsmide; MTX,
methotrexate; VCR, vincristine; ADR, adriamycin; PRO, procarbazine; s, growth in
suspension; mon, growth as monolayer. *D. Carney (personal communication).
before sensitivity testing (Jensen et al., 1989). A single-cell
suspension was exposed to each of the drugs for 1 h, washed
twice with PBS (150 mM NaCl, 50 mM phosphate, pH 7.2), and
plated in soft agar on top of a feeder layer containing sheep
red blood cells. After solidification of the agar, 1 ml of
medium was added to prevent drying. In each experiment the
four drugs were tested on the same batch of cells. The
stability of the cytotoxicity of the drugs was assessed in
experiments comparing 1-h cytotoxicity of drug solutions
preincubated 48 h in tissue culture medium at 37°C with
freshly diluted drugs. For continuous incubation, the cells
were plated directly in agar with the desired drug concentra-
tion. The colonies were counted after three weeks incubation.
Data analysis
For each drug the cells were exposed to five concentrations.
All experiments were done in triplicate. To obtain linearity
on exponential dose-response curves the logarithmically
transformed response data were used in linear regression
analysis. When a large shoulder was obtained on the
dose-response curves only the exponential parts of these
curves were used in the analysis. When the intercept of the
regression line was below the survival of untreated cells
(100% survival) the regression line was recomputed without
intercept. The dose reducing the number of colonies to 50%
of control (LD50) was computed from the regression
parameters.
Flow cytometric DNA-analysis
Cell samples for flow cytometric DNA-analysis were taken
from the single-cell suspensions just before drug exposure.
After centrifugation, the cells were suspended in citrate
buffer, frozen on ethanol with dry ice and stored at - 80°C
until analysis (Vindel0v et al., 1983a). The samples were
stained with propidium iodide (Vindel0v et al., 1983b) and
analysed in a FACS III flow-cytometer (Becton-Dickinson).
The percentage of cells in each cell cycle phase was deter-
mined by statistical analysis of the DNA distribution
(Christensen et al., 1978).
Immunological detection ofP-glycoprotein
C219 monoclonal antibody (1 mg ml-') against P-
glycoprotein (Kartner et al., 1985) was purchased from Cen-
tocor (Malvern, PA, USA). Peroxidase conjugated antibody
was purchased from Dakopatts, Copenhagen.
Western blot Cells from all human cell lines were spun
down at 150g and washed with PBS. The cell pellets were
then resuspended (v/v 2:3) in a solution consisting of 3.4 mM
sodium citrate, 1.5 mM spermine tetrahydrochloride, 0.5 mM
Tris and 1% v/v Nonidet P40 (pH 7.6). After centrifugation
at 1,400g, 35 fil of the supernatants were loaded on to a
10% (w/w) SDS-PAGE gel with 0.1% (w/w) SDS. Proteins
were blotted on to nitrocellulose paper after electrophoresis.
The paper was washed in a 150 mM NaCl, 50 mM Tris
(pH 7.4) buffer containing 3% (w/w) bovine serum albumin,
and 0.1% (v/v) Tween 20, and probed overnight at 4°C with
the C219 antibody at 1:400 dilution. Peroxidase conjugated
rabbit anti-mouse antibody (Dako P260) was used as the
secondary antibody at a dilution of 1:250 applied for 2 h.
The blot was developed using 3-amino-9-ethyl carbazole as
chromogen. Controls were performed by omission of the
primary antibody.
Immunohistochemistry Cell from all human lines were
pelleted and frozen sectioned. Frozen sections were fixed in
acetone for 15min. Thereafter a three layer immunohis-
tochemical technique was employed, the first layer being
C219 antibody 1:500 overnight at 4°C, the second layer
peroxodise conjugated rabbit anti-mouse 1:10 (Dako P260),
and the third layer peroxidase conjugated swine anti-rabbit
1:20 (Dako P217) with washes of PBS in between. 3-Amino-
9-ethyl carbazole was used as chromogen and Mayer's
haematoxylin counterstain. Controls were performed by
omission of the primary antibody.
Results
We have previously shown that the sensitivity of the SCCL
cell lines to ADR, DAU and MITO with 1-h incubation is
dependent on the size of the S-phase fraction at the time of
drug exposure and that reduced variation in the clonogenic
assay can be obtained by standardisation of the cell culture
conditions (Jensen et al., 1989). In the present study, the
inter-experimental variation after continuous incubation was
evaluated on cell line NCI-N592 in three experiments with
varying S-phase distribution (Table II). Despite a variation
with a factor of two in the S-phase distribution, the inter-
experimental variation in LD50 is less than 25% and not
correlated to the size of the S-phase. With similar S-phase
variations the sensitivity with 1-h incubation varied 250%
(Jensen et al., 1989). Accordingly , standardisation of the
growth conditions before sensitivity testing with continuous
incubation is not necessary. The results of continuous
incubation with ACLA, ADR, DAU and MITO on the eight
SCCL lines and the two murine cell lines Ehrlich ascites
tumour and P388 leukaemia are shown in Figure 1. For
comparison the results with 1-h incubation are depicted in
Figure 2. The cell lines are ranked according to the sensitivity
obtained with 1-h ADR exposure. As with 1-h incubation,
the Ehrlich ascites tumour is the least sensitive cell line
to ADR and P388 leukaemia the most sensitive cell line to
ADR. Likewise the murine tumours are relatively sensitive
to MITO and relatively insensitive to ACLA. This high
sensitivity to MITO on the murine tumours is in accordance
with previous findings (Hill et al., 1989). Although NCI-H69
is relatively more sensitive to DAU, the sensitivity to ADR
and DAU covariate and is almost equal in most cell lines,
whereas DAU is more potent than ADR with 1-h incubation.
MITO is a potent drug with continuous incubation and the840 P.B. JENSEN et al.
Table II Variation in S-phase distribution and sensitivity to
adriamycin, daunorubicin, aclarubicin and mitoxantrone of cell line
NCI-N592 in three experiments with continuous incubation.
LD5o (ygml-')
% Sphase ADR DAU ACLA MITO
19 0.018 0.016 0.0058 0.0056
27 0.015 0.015 0.0057 0.0058
34 0.016 0.015 0.0045 0.0057
jig ml-1 ,ug ml-'
relative sensitivity covariates with ADR and DAU. The most
striking change from 1-h to continuous drug exposure is the
relatively high and uniform potency of ACLA. ACLA is the
most potent drug in the three SCCL cell lines least sensitive
to ADR. By comparing Figure 1 with Figure 2, only minor
changes in the sensitivity pattern of ADR and MITO are
seen. Apart from the low ACLA sensitivity of Ehrlich ascites
tumour cells, all other cell lines seem relatively sensitive to
ACLA with continuous drug exposure. In the human cell
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Figure 1 The sensitivity of eight human SCCL and two murine ascites tumour cell lines to ADR, DAU, ACLA and MITO.
Continuous drug exposure. The results are depicted as LD50 values. The units on the histograms are calibrated according to the
mean LD50 of the individual drug to enable the comparison of patterns in sensitivity. Cell lines NCI-H69, NCI-H249CL5, GLC-16
and NCI-N592 were established from treated patients (Table I). EHR (Ehrlich ascites tumour) 69 (NCI-H69), H249 (NCI-
H249CL5), TOL (OC-TOL), 592 (NCI-N592), N417 (NCI-N417), NYH (OC-NYH) and 86M1 (SCLC-86M1).
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Figure 2 The sensitivity of eight human small cell and two murine ascites tumour cell lines to ADR, DAU, ACLA and MITO.
One-hour drug exposure. The cell lines are ranked according to increasing ADR sensitivity. Observe the increased drug
concentrations used compared to Figure 1.
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lines, the patterns of 1-h incubation and continuous incuba-
tion indicate cross-resistance between ADR, DAU and
MITO, whereas the sensitivity pattern to ACLA is different.
With 1-h incubation, the average LD50 value obtained with
ACLA on the 10 cell lines is 0.39 lgml-' and with con-
tinuous incubation it was 0.077 gg ml-'. The potency of
ACLA is thus increased by a factor of 51. The potency of
MITO, ADR and DAU are increased by factors of only 16,
13 and 6 respectively.
The sensitivity of the DAU resistant cell lines NCI-H69/
DAU4 and NCI-H69/DAU8 was assessed with continuous
incubation (Figure 3). Compared to the parental line, the
resistant cell lines are cross-resistant to ADR and partially
resistant to MITO and ACLA. Resistance to anthracyclines
has been attributed to a 'leak and pump' model of the cell
membrane with an active efflux of the anthracyclines pro-
posed to be linked to a glycoprotein (P-glycoprotein) in the
cell membrane (Bradley et al., 1988). Western blot analysis
with the monoclonal antibody C-219 directed against the
P-glycoprotein was performed on all the human cell lines.
There was no detectable staining for P-glycoprotein on the
wild type lines (not shown). In the resistant lines there was
barely detectable glycoprotein on NCI-H69/DAU8 whereas
the glycoprotein was clearly discernible on cell line NCI-H69/
DAU4 (Figure 4). Based on the dilution shown in Figure 4
the limit of detection is between 5 and 10% of the amount
seen in NCI-H69/DAU4, and it is seen that NCI-H69/DAU8
has less than 10% of the P-glycoprotein found in NCI-H69/
DAU4. Likewise the use of immunohistochemistry did not
recognise P-glycoprotein on the wild type cell lines or on
NCI-H69/DAU8 and confirmed the Western blot detection
of P-glycoprotein in NCI-H69/DAU4 (not shown).
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Discussion
In this panel ofeight SCCL cell lines established from treated
and untreated patients the sensitivities to the four drugs vary
within a factor of only five. Thus, a minimal inter-
experimental variation is necessary in establishing sensitivity
profiles from a panel of cell lines. With short time incuba-
tion, the variation is mainly due to variations in the S-phase
fraction. Consequently it is necessary to standardise growth
conditions before sensitivity testing to reduce the variation in
the S-phase fraction. The present investigation has shown
that the inter-experimental variation with continuous incuba-
tion is small and not correlated to the size of the S-phase
fraction at the start of the incubation. This finding is in
accordance with the longer drug exposure time, ensuring that
all cells pass through sensitive cell-cycle phases.
The almost identical sensitivity patterns obtained after 1-h
incubation and continuous incubation strongly support the
value of continuous incubation. A limited drug stability
leading to poorly defined concentration-time products is,
however, an obvious problem in interpreting data from
experiments with continuous incubation. There seem to be no
major differences in the stability of DAU, ACLA and MITO
is physiological solutions. Thus DAU, ACLA and MITO are
95% stable in neutral 150 mM NaCl solutions at room
temperature for 40, 52 and more than 48 h respectively
(Bosanquet, 1986). As shown by Bosanquet, no consensus
exists in the literature regarding the stability of ADR, which
has been most extensively studied, and it is suggested that
similar discrepancies would be found if the other drugs were
investigated as intensively. Therefore we tested the stability
of the cytotoxicity of DAU and ACLA by comparing the
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Figure 3 Dose-response curves obtained with continuous incubation of ACLA (a), ADR (b), DAU (c) and MITO (d) on the
DAU-resistant sublines NCI-H69/DAU4 (------) and NCI-H69/DAU8 (---) compared to the parental cell line NCI-H69
). Regression analysis gave the following LD50 values for: DAU, 0.011, 0.047 and 0.105 tg ml-; ACLA, 0.0050, 0.014 and
0.019 ugml-' on NCI-H69, NCI-H69/DAU8, and NCI-H69/DAU4 respectively.
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Figure 4 Western blot detection of P-glycoprotein with C219 monoclonal antibody. 1, P388 sensitive and, 2, P388/DAU +
daunorubicin resistant murine controls. In the sensitive line C219 binds to protein with a lower molecular weight than P-
glycoprotein; 3, the parental cell line NCI-H69; 4, subline NCI-H69/DAU8; 5, subline NCI-H69/DAU4; 6, 75%; 7, 50%; 8, 25%;
9, 10%; 10, 5% dilution of the protein loaded to lane 5; 11, Ehrlich/DAU + daunorubicin resistant and 12, wild type Ehrlich
ascites tumour murine controls.
activity of freshly diluted drugs with drugs preincubated
for 48 h at 37°C in medium. In two experiments on cell
lines NCI-H69 and NCI-N592 with 1-h drug exposure we
found a 20 and 25% increase in the LD50 value of ACLA
and a 3 and 5% increase in the LD50 value of prein-
cubated DAU. Thus the relative increase in potency with
continuous incubation cannot be explained by a higher
stability of ACLA than of DAU. A possible explanation
of the increase in potency elicited by ACLA with pro-
longed exposure time could be that ACLA preferentially
inhibit RNA synthesis, especially nucleolar RNA synthesis
(Skovsgaard, 1987; Oki et al., 1981), in contrast to ADR
and DAU, which inhibit DNA- and RNA-synthesis to
almost the same degree.
In vitro resistance and cross-resistance to ACLA have been
studied in a number of anthracycline-resistant murine and
human tumour cell lines (Table III). Development of resis-
tance to ACLA in the L5178Y cell line was accompanied by
a reduction in the sensitivity to DAU and ADR (Nishimura
et al., 1980). However, only minimal cross-resistance was
found in a range of human and murine cancer cell lines
highly resistant to DAU and ADR (Nishimura et al., 1978;
Hill et al., 1985; Umezawa et al., 1987; Scott et al., 1986;
Twentyman et al., 1986) (Table III). In vivo, ACLA was
found to be effective in P388 resistant to m-AMSA (Johnson
& Howard, 1982) and some activity was reported on P388
resistant to ADR (Oki et al., 1981). In contrast, ACLA was
ineffective in vivo against Ehrlich ascites tumour resistant to
DAU (Skovsgaard, 1987). We have compared the DAU
resistant subline of Ehrlich ascites tumour to the wild type in
vitro. The LD50 of ACLA was increased by a factor of 2.3
whereas a 20-fold increase was found with DAU. Since the
Ehrlich wild type is not very sensitive to ACLA, such a low
decrease in ACLA sensitivity is sufficient to result in total
loss of activity. The sublines NCI-N69/DAU4 and NCI-H69/
DAU8 are cross-resistant not only to ADR and MITO, but
also to ACLA. However, as seen in Figure 3, both H69/
DAU8 and H69/DAU4 are more sensitive to ACLA than to
Table III Relative resistance in drug resistant cancer cell lines
In vitro resis-
Cell Resistant tancefactor' In vivo
Reference line Type to ACLA DAU ADR ACLA DAU ADR
Nishimura et al. (1980) L5178Y MUR ACLA 11 27 42
Nishimura et al. (1978) ADR 2 20 20
Hill et al. (1985) ADR 1.2 2.5 2.5
Umezawa et al. (1987) P388 - ADR 1.6 22 26
Scott et al. (1986) - ADR 1.4 - 14
Johnson & Howard (1982) - M-AMSA - - SEN PR RES
Oki et al. (1981) - ADR - - - PR
Skovsgaard (1987) EHRLICH - DAU 2.3b 20b 60b RES RES
Scott et al. (1986) CCRF CEM HUM ADR 1.2 5.7
Scott et al. (1986) U266BL - ADR 1.2 - 9.3
Twentyman et al. (1986) NCI-H69 - ADR 0.8-1.1 - 5-25
Twentyman et al. (1986) - - ADR 2.3 - 50
- - DAU 2.9c 4.4C -
- - DAU 3.8c 9.4C -
MUR,murine; HUM,human; SEN, sensitive; PR,partiallyresistant; RES, resistant. aThe in vitroresistance
factor is the ratio between doses giving the same effect in the resisted cell line and in the parent cell line. bE.
Friche (unpublished results). cResults from the present investigation.
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ADR or DAU. Although accurate LD50 values cannot be
determined because of the limited cell kill obtained with
DAU in the resistant cell lines, it is clear that the relative
resistance to DAU is more pronounced than to ACLA and
MITO. Thus these results and the results summarised in
Table III all suggest limited cross-resistance to ACLA in
tumour cell lines made resistant to ADR or DAU. As the
parental cell line NCI-H69 was obtained from a patient who
had been heavily pretreated with ADR (Table I) the clinical
relevance of the increased resistance of the sublines may be
limited. No P-glycoprotein was detected on the wild type
lines, whereas the protein was abundant in NCI-H66/DAU4.
The ACLA sensitivity of NCI-H69/DAU8, with 10% or less
P-glycoprotein content compared to NCI-H69/DAU4, is
similar to the ACLA sensitivity of NCI-H69/DAU4. Thus
there seems to be no linear relationship between the amount
of P-glycoprotein and the resistance to ACLA. In this con-
text it is interesting that only a modest reduction of ACLA
accumulation has been found in cell lines resistant to ACLA
(Skovsgaard, 1987).
The clinical results of ACLA treatment in solid tumours
have been disappointing so far. The drug has not shown
activity against a range of tumours (Aabo et al., 1983;
Woolley et al., 1982; Kerpel-Fronius et al., 1987) including
SCCL (Lev & Posada, 1983; Kramer et al., 1986; Abeloff et
al., 1985). The doses have invariably been significantly lower
in the solid tumour trials (e.g. 100 mg m-2 as a bolus treat-
ment) compared to the high doses of ACLA that have been
used in leukaemia trials (e.g. 80 mg m-2 for three consecutive
days). In this context it has been demonstrated (Machover et
al., 1984) that the cumulative dose required for the majority
of previously treated leukaemia patients to achieve complete
remission is > 300 mg m2. Machover et al. (1984) used
10-day courses of ACLA at a daily dose of 15 mg m-2 with
10-day intervals between courses. This regimen was given to
25 patients with AML who were either refractory to initial
induction chemotherapy or in relapse. Eleven patients (44%)
achieved complete remission. These results are comparable to
the results obtained with shorter schedules using considerably
higher doses. Although optimal schedules cannot be deter-
mined in vitro, the present study also indicates a relative
increase in ACLA potency with prolonged administration.
However, the importance of a prolonged schedule still re-
mains to be determined in a randomised trial.
If sensitivity patterns on cell lines obtained from treated
and untreated patients with SCCL give a reliable picture of
the disease, the lack of ACLA resistance on the panel of
SCCL cell lines and the potency of ACLA seen with pro-
longed administration justify new clinical trials of ACLA
against SCCL. In favour of this approach is also the great
difficulty in obtaining in vitro resistance to ACLA that has
been described from different groups. Tapiero et al. (1988)
took 3 years to obtain a 6-fold ACLA resistant cell line,
whereas a 100-fold ADR resistant cell line was obtained in a
month. Likewise, Nishimura et al. (1980) tried without suc-
cess to isolate ACLA resistant cells in vitro. We have recently
initiated a phase II trial of ACLA on patients with relapse of
SCCL using the high leukaemia doses in a three day schedule
as this schedule has been most thoroughly tested.
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